EUDRAVIGILANCE at 1327876 VAERS at 698193 Glycine N-Acetylcysteine   Parkinsons Omicron Negative VE
Channel: VHFILM
Date: 02/01/2022

00:01 Open with the study quote: ' may exhibit neurological symptoms of synucleinopathies diagnosed as Parkinson’s disease and/or Lewy body dementia up to two to three decades post-immunization "
02:21 Brief look at Vaccine Negative Effectiveness vs Omicron
05:59 Forward look at what will be covered
10:49 VAERS Disclaimer and other DATA sources
12:45  Quote: "Therefore, the findings of this study are interesting because they show a much more widespread prevalence of GSH (Glutathione) deficiency in all age groups of adult humans hospitalized with COVID-19, especially in younger humans" ( Translational Metabolism Unit, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Baylor College of Medicine )
18:01 Immune response to seasonal coronaviruses may offer protection against COVID-19 (RIKEN)
18:36 Omicron infection enhances neutralizing immunity against the Delta variant ( Africa Health Research Institute, Durban, South Africa.)
23:04 Animal study - OMICRON - does not seem to readily infect lungs or organs ( KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for
5 Medical Research, Laboratory of Virology and Chemotherapy, )
25:33 Quote:  In contrast, receipt of 2 doses of COVID-19 vaccines was not protective against Omicron infection at any point in time, and VE was–38% (95%CI, –61%, –18%) 120-179 days and –42% (95%CI, –69%, –19%) 180-239 days after the second dose. VE against Omicron was 37% (95%CI, 19-50%) ≥7 days after receiving an mRNA vaccine for the third dose. ( Public Health Ontario, Toronto, ON )
34:48 Boosters Quote: in the second month and became small and insignificant in the third to fourth months. ( Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel)
36:59 Children being devastated by hand sanitizers and disinfectants
40:43 Quote: Toll-like receptors, which are activated by mRNA vaccines, cause significant changes in cytokine and gene expression beginning within hours after receptor activation, peak within 6 to 24 h, and subside over the following 48 to 168 h [31], consistent with this patient’s disease timeline.( Department of Radiology, Boston Children’s Hospital and Harvard Medical School)
45:11 Quote: Therefore, a theoretical scenario exists where a certain proportion of people receiving the COVID-19 vaccine, likely from among those with neurological side effects (e.g., severe headaches), may exhibit neurological symptoms of synucleinopathies diagnosed as Parkinson’s disease and/or Lewy body dementia up to two to three decades post-immunization ( Scientific and Regulatory Consultant, Rigaud, QC J0P 1P0, Canada )
51:24 ONWARD TO DATA

Data Sources:
GISAID
HEALTHDATA GOV
CDC
OUR WORLD IN DATA
VAERS
EUDRAVIGILANCE
#glynac #omicron #neurological

Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation. Antioxidants. 2022; 11(1):50. https://doi.org/10.3390/antiox11010050

Immune response to seasonal coronaviruses may offer protection against COVID-19
 Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2. Commun Biol 4, 1365 (2021). https://doi.org/10.1038/s42003-021-02885-6

Omicron infection enhances neutralizing immunity against the Delta variant
medRxiv 2021.12.27.21268439; doi: https://doi.org/10.1101/2021.12.27.21268439

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
bioRxiv 2021.12.24.474086; doi: https://doi.org/10.1101/2021.12.24.474086

Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV)
Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Euro Surveill. 2019 Nov;24(46):1900585. doi: 10.2807/1560-7917.ES.2019.24.46.1900585. PMID: 31771709; PMCID: PMC6864978.

Effectiveness of COVID-19 vaccines against Omicron or Delta infection
medRxiv 2021.12.30.21268565; doi: https://doi.org/10.1101/2021.12.30.21268565

Waning of SARS-CoV-2 booster viral-load reduction effectiveness
 medRxiv 2021.12.27.21268424; doi: https://doi.org/10.1101/2021.12.27.21268424

Analysis of Consumer Exposure Cases for Alcohol-Based Disinfectant and Hand Sanitizer Use against Coronavirus Disease 2019 (COVID-19). International Journal of Environmental Research and Public Health. 2022; 19(1):100. https://doi.org/10.3390/ijerph19010100

Multisystem Inflammatory-like Syndrome in a Child Following COVID-19 mRNA Vaccination. Vaccines. 2022; 10(1):43. https://doi.org/10.3390/vaccines1001004

How Does Severe Acute Respiratory Syndrome-Coronavirus-2 Affect the Brain and Its Implications for the Vaccines Currently in Use. Vaccines. 2022; 10(1):1. https://doi.org/10.3390/vaccines10010001